Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium

Introduction for Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Antibody Testing in Germany

Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients

SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months

Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2

Diagnostic Tool for Coronavirus Being Developed by University of Warwick

Saliva could be an alternative fluid to test COVID-19 antibodies

Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area